Every great scientific revolution begins when humanity learns to re-engineer the materials of life itself. **VIONIX ZERO** is that revolution for pharmaceutical manufacturing; a UK-born project uniting _biology, artificial intelligence, and circular design_ to create the world's first blueprint for **bio-intelligent, zero-waste drug production**. Its goal is simple but radical: to ensure that every molecule, material, and process in medicine manufacturing can be reused, regenerated, or reborn. **Founded by Varun Cruz, a 25-year-old British entrepreneur known for bridging advanced AI, biotechnology, and sustainable design**, VIONIX Pharma Ltd leads this initiative as part of the UK's next generation of clean-manufacturing innovators. Pharmaceutical manufacturing contributes around **55 % of a medicine's total carbon footprint** and produces **hundreds of thousands of tonnes of solvent and packaging waste each year** (Royal Society of Chemistry, 2024). Whilst energy efficiency has advanced, material efficiency has not, and most of the industry still operates on a "take--make--dispose" model. **VIONIX ZERO** aims to transform that system into a _closed-loop ecosystem_ where manufacturing waste becomes the feedstock for tomorrow's products. The project will test two interconnected prototypes: 1. **Pilot ZERO** -- an AI-driven recovery module designed to recycle solvents and excipients from pharmaceutical waste streams, targeting a **20 % reduction in material losses** and a **15 % reduction in emissions** per batch. 2. **Material ZERO** -- a seaweed- and cellulose-based bio-film that is both _biodegradable_ and _responsive_, changing colour or conductivity to indicate humidity or product stability. Together, these innovations form a **new materials-intelligence layer** for the life-sciences industry, packaging that senses its environment and production systems that learn to eliminate waste. All R&D will be conducted within the UK in collaboration with **the University of Leeds' School of Chemical and Process Engineering** and **the University of Derby's Institute for Innovation in Sustainable Engineering**, ensuring regional capability building, faster scale-up, and alignment with national decarbonisation goals. Beyond pharmaceuticals, the findings have direct relevance to **biotech, cosmetics, and nutraceutical manufacturing**, positioning the UK as a world leader in sustainable, high-value materials science. By combining **resource-efficient materials, smart design, AI, and digital circularity**, **VIONIX ZERO** advances _Innovate UK's Manufacturing Vision 2050_ and the _UK Industrial Decarbonisation Strategy (2023)_ , demonstrating how British innovation can turn waste into intelligence and redefine what "net-zero" truly means.

PHARMORIS® is a digital platform being developed by NEUVIOR Pharmaceuticals Ltd, a UK incorporated, pharmaceutical and technology company, focused on improving access and resilience across healthcare systems. Founded by 25 year old, neurodivergent, British entrepreneur, Varun Cruz; NEUVIOR develops pharmaceutical supply intelligence and digital regulatory systems to support more efficient delivery of medicines in the UK and internationally. This project focuses specifically on the development of PHARMORIS, the company’s first commercial platform. PHARMORIS is an AI enabled decision support platform designed to improve how generic medicines are identified and progressed through regulatory pathways for the NHS and wider health systems. The platform applies deep tech to structured data models and analytical methods, to support more efficient preparation and management of regulatory submissions, including electronic Common Technical Document (eCTD) workflows, informed by patent landscape, pricing, and supply intelligence. The NHS spends over £17 billion per year on medicines, with generic medicines accounting for approximately 75% of all prescriptions. Despite this, delays between patent expiry and NHS adoption of generics often range from 6 to 12 months, and more than 150 medicines experienced supply shortages in 2024. These delays and disruptions create avoidable costs and limit timely patient access to essential treatments. PHARMORIS addresses these challenges by bringing together NHS prescribing data, medicine pricing, patent timelines, and regulatory information into a single integrated platform. This enables earlier identification of priority medicines, clearer regulatory pathways, and more coordinated planning across stakeholders involved in generic medicine supply. This replaces manual, fragmented regulatory and supply workflows with an integrated, data driven decision support process. The platform is being developed with a strong emphasis on governance, auditability, and regulatory compliance, with the aim of supporting faster, more resilient access to generic medicines whilst aligning with NHS procurement and supply chain requirements. By April 2026, the project will deliver a working prototype capable of identifying high priority generic medicines, streamlining e-CTD regulatory workflows, and supporting improved supply resilience across the UK pharmaceutical system. The project contributes to UK priorities in pharmaceutical innovation, digital transformation, cost efficiency, and healthcare system resilience, and aims to provide a blueprint for a more sustainable national medicines infrastructure.